Clinical Trials Arena on MSN

Bayer’s cell therapy shows 3-year improvement in Phase I Parkinson’s trial

The drug will now progress to pivotal Phase III trials after demonstrating trends towards a disease-modifying impact.
Morningstar

Bayer Initiates Phase I Study Targeting GPC3 With Actinium-225 Radiopharmaceutical in Patients With Advanced Hepatocellular Carcinoma

Bayer announced today initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing Glypican-3 ...
Reuters

Bayer adds cancer drug candidate to portfolio with $1.3-billion Kumquat deal

BERLIN, Aug 12 (Reuters) - German pharmaceutical group Bayer (BAYGn.DE), opens new tab announced on Tuesday a deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology ...
Hosted on MSN

Bayer to Pay $1.3 Billion for Cancer Medicine in Pharma Push

(Bloomberg) -- Bayer AG agreed to pay Kumquat Biosciences Inc. as much as $1.3 billion to gain a potential new cancer medicine and boost its pharma division’s growth prospects. The German company will ...
Reuters

Bayer adds $1.37 billion to Roundup litigation reserves, raises 2025 sales forecast

July 31 (Reuters) - German pharmaceutical and biotechnology group Bayer (BAYGn.DE), opens new tab said on Thursday it had set aside an additional 1.2 billion euros ($1.37 billion) in provisions to ...